Mechanisms of Persistence and Recovery in Otitis Media

中耳炎的持续和恢复机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): Otitis media (OM) is a major health problem, resulting in substantial health care expenditures. More than 90% of children experience OM. While acute, uncomplicated OM tends to be self-limiting, 10- 20% of children experience persistent, recurrent or chronic disease. The long-lasting forms of this condition produce hearing loss during critical periods of language acquisition and learning, and carry a risk for permanent damage to the middle and inner ear. Current treatments, including prophylactic or repeated antibiotics and surgical interventions, are controversial, underscoring the need for additional therapies. The causes of persistent OM, and why some children progress to persistent or recurrent disease while others experience only one or a few episodes of acute OM, are not clear. However, mechanisms that contribute to other forms of chronic inflammatory diseases have recently been identified. These include mutations or polymorphisms in genes that subserve innate immunity, defects in cellular processes that control infection such as phagocytosis, and dysregulation of cellular and tissue systems that promote recovery from inflammation. Data obtained during the current period of support suggest the involvement of these mechanisms in persistent OM, as well. OM in mice with mutations in several innate immune genes fail to recover normally from OM. Moreover, OM persistence is correlated with changes in the behavior and function of macrophages. Finally, genes encoding pro-recovery monocyte phenotypes, as well as pro-recovery factors and their receptors, are up-regulated during the recovery phase of OM. In this application Drs. Stephen Wasserman, Allen Ryan and Eyal Raz propose a series of integrated experiments employing genetically modified mice to identify cellular and molecular mechanisms that lead to chronic OM, and to explore novel therapies for this condition. Aim 1 of this application will assess the contributions of innate immune NOD-like receptor (NLR) signaling pathways to OM pathogenesis and recovery. Aim 2 will investigate the role of different phenotypes of monocyte-derived cells, including macrophages and dendritic cells, in OM. Aim 3 will elucidate the mechanisms by which recovery from inflammation is regulated in the middle ear (ME), and determine whether pro-recovery factors can ameliorate acute and persistent ME disease. Together these studies will expand our understanding of how OM recovery can fail, and how this failure can be reversed.
描述(由申请人提供):中耳炎(OM)是一个主要的健康问题,导致大量的医疗保健支出。超过90%的儿童经历过OM。虽然急性、无并发症的OM往往是自限性的,但10- 20%的儿童患有持续性、复发性或慢性疾病。这种情况的长期形式会在语言习得和学习的关键时期造成听力损失,并有可能对中耳和内耳造成永久性损伤。目前的治疗方法,包括预防性或反复使用抗生素和手术干预,是有争议的,强调需要额外的治疗。持续性OM的原因,以及为什么有些儿童进展为持续性或复发性疾病,而其他儿童只经历一次或几次急性OM发作,尚不清楚。然而,最近已经确定了导致其他形式的慢性炎症性疾病的机制。这些包括有助于先天免疫的基因突变或多态性,控制感染的细胞过程如吞噬作用的缺陷,以及促进炎症恢复的细胞和组织系统的失调。在目前的支助期间获得的数据表明,这些机制也参与了持久性OM。在几个先天免疫基因突变的小鼠中,OM不能从OM中正常恢复。此外,OM持续性与巨噬细胞行为和功能的变化相关。最后,编码促恢复单核细胞表型的基因以及促恢复因子及其受体在OM的恢复期期间上调。在本申请中,Stephen Wasserman博士、艾伦瑞恩博士和Eyal Raz博士提出了一系列采用转基因小鼠的综合实验,以鉴定导致慢性OM的细胞和分子机制,并探索这种疾病的新疗法。本申请的目的1将评估先天免疫NOD样受体(NLR)信号通路对OM发病机制和恢复的贡献。目的2探讨不同表型的单核细胞源性细胞(包括巨噬细胞和树突状细胞)在OM中的作用。目的3将阐明中耳(ME)炎症恢复的调节机制,并确定促恢复因子是否可以改善急性和持续性ME疾病。这些研究将扩大我们对OM恢复如何失败以及如何逆转这种失败的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen I Wasserman其他文献

Biochemical Mediators Of Immediate Type Hypersensitivity
  • DOI:
    10.1111/1523-1747.ep12543934
  • 发表时间:
    1976-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Stephen I Wasserman
  • 通讯作者:
    Stephen I Wasserman

Stephen I Wasserman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen I Wasserman', 18)}}的其他基金

ASTHMA CLINICAL RESEARCH NETWORK
哮喘临床研究网络
  • 批准号:
    6676585
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
Mast Cells and innate immunity in otitis media
肥大细胞和中耳炎的先天免疫
  • 批准号:
    6895928
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
Mast Cells and innate immunity in otitis media
肥大细胞和中耳炎的先天免疫
  • 批准号:
    6677222
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
ASTHMA CLINICAL RESEARCH NETWORK
哮喘临床研究网络
  • 批准号:
    8401835
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
Mast Cells and innate immunity in otitis media
肥大细胞和中耳炎的先天免疫
  • 批准号:
    6765251
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
ASTHMA CLINICAL RESEARCH NETWORK
哮喘临床研究网络
  • 批准号:
    6946816
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
ASTHMA CLINICAL RESEARCH NETWORK
哮喘临床研究网络
  • 批准号:
    7283172
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
Mast Cells and innate immunity in otitis media
肥大细胞和中耳炎的先天免疫
  • 批准号:
    7233580
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
Mast Cells and innate immunity in otitis media
肥大细胞和中耳炎的先天免疫
  • 批准号:
    7082158
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:
Mechanisms of Persistence and Recovery in Otitis Media
中耳炎的持续和恢复机制
  • 批准号:
    8020983
  • 财政年份:
    2003
  • 资助金额:
    $ 30.19万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 30.19万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了